{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:30:09Z","timestamp":1764603009433},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T00:00:00Z","timestamp":1275004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00432-010-0915-7","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T05:47:13Z","timestamp":1274939233000},"page":"543-550","source":"Crossref","is-referenced-by-count":15,"title":["Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer"],"prefix":"10.1007","volume":"137","author":[{"given":"Mary A.","family":"Bewick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Lafrenie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S. C.","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,28]]},"reference":[{"key":"915_CR1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0304-3835(00)00532-2","volume":"159","author":"SZ Abdel-Rahman","year":"2000","unstructured":"Abdel-Rahman SZ, El-Zein RA (2000) The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 159:63\u201371","journal-title":"Cancer Lett"},{"key":"915_CR2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/em.20032","volume":"44","author":"AA Affatato","year":"2004","unstructured":"Affatato AA, Wolfe KJ, Lopez MS et al (2004) Effect of XPD\/ERCC2 polymorphisms on chromosome aberration frequencies in smokers and on sensitivity to the mutagenic tobacco-specific nitrosamine NNK. Environ Mol Mutagen 44:65\u201373","journal-title":"Environ Mol Mutagen"},{"key":"915_CR3","first-page":"959","volume":"14","author":"R Altaha","year":"2004","unstructured":"Altaha R, Liang X, Yu JJ et al (2004) Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14:959\u2013970","journal-title":"Int J Mol Med"},{"key":"915_CR4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/0008-5472.1105.65.3","volume":"65","author":"CB Ambrosone","year":"2005","unstructured":"Ambrosone CB, Ahn J, Singh KK et al (2005) Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 65:1105\u20131111","journal-title":"Cancer Res"},{"key":"915_CR5","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/bcr1526","volume":"8","author":"CB Ambrosone","year":"2006","unstructured":"Ambrosone CB, Tian C, Ahn J et al (2006) Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res 8:R40","journal-title":"Breast Cancer Res"},{"key":"915_CR6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s002800050504","volume":"38","author":"BS Andersson","year":"1996","unstructured":"Andersson BS, Sadeghi T, Siciliano MJ et al (1996) Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 38:406\u2013416","journal-title":"Cancer Chemother Pharmacol"},{"key":"915_CR7","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1289\/ehp.6632","volume":"111","author":"WW Au","year":"2003","unstructured":"Au WW, Salama SA, Sierra-Torres CH (2003) Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 111:1843\u20131850","journal-title":"Environ Health Perspect"},{"key":"915_CR8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1078\/1438-4639-00294","volume":"207","author":"WW Au","year":"2004","unstructured":"Au WW, Navasumrit P, Ruchirawat M (2004) Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health 207:301\u2013313","journal-title":"Int J Hyg Environ Health"},{"key":"915_CR9","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1349-7006.2007.00557.x","volume":"98","author":"K Azuma","year":"2007","unstructured":"Azuma K, Komohara Y, Sasada T et al (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336\u20131343","journal-title":"Cancer Sci"},{"key":"915_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/aje\/kwi018","volume":"161","author":"S Benhamou","year":"2005","unstructured":"Benhamou S, Sarasin A (2005) ERCC2\/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 161:1\u201314","journal-title":"Am J Epidemiol"},{"key":"915_CR11","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1200\/JCO.2006.05.9923","volume":"24","author":"MA Bewick","year":"2006","unstructured":"Bewick MA, Conlon MS, Lafrenie RM (2006) Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 24:5645\u20135651","journal-title":"J Clin Oncol"},{"key":"915_CR12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10549-007-9764-8","volume":"111","author":"MA Bewick","year":"2008","unstructured":"Bewick MA, Conlon MS, Lafrenie RM (2008) Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat 111:93\u2013101","journal-title":"Breast Cancer Res Treat"},{"key":"915_CR13","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1002\/cncr.21885","volume":"106","author":"R Booton","year":"2006","unstructured":"Booton R, Ward T, Heighway J et al (2006) Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 106:2421\u20132427","journal-title":"Cancer"},{"key":"915_CR14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/FPC.0b013e32832f3010","volume":"19","author":"PA Bradbury","year":"2009","unstructured":"Bradbury PA, Kulke MH, Heist RS et al (2009) Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 19:613\u2013625","journal-title":"Pharmacogenet Genomics"},{"key":"915_CR15","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ijrobp.2006.06.029","volume":"66","author":"J Carles","year":"2006","unstructured":"Carles J, Monzo M, Amat M et al (2006) Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 66:1022\u20131030","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"915_CR16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/tpj.2009.19","volume":"9","author":"D Caronia","year":"2009","unstructured":"Caronia D, Patino-Garcia A, Milne RL et al (2009) Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 9:347\u2013353","journal-title":"Pharmacogenomics J"},{"key":"915_CR17","first-page":"843","volume":"9","author":"P Chen","year":"2000","unstructured":"Chen P, Wiencke J, Aldape K et al (2000) Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9:843\u2013847","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"915_CR18","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.2008.17.4839","volume":"27","author":"HK Chew","year":"2009","unstructured":"Chew HK, Doroshow JH, Frankel P et al (2009) Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 27:2163\u20132169","journal-title":"J Clin Oncol"},{"key":"915_CR19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/carcin\/21.5.965","volume":"21","author":"EJ Duell","year":"2000","unstructured":"Duell EJ, Wiencke JK, Cheng TJ et al (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21:965\u2013971","journal-title":"Carcinogenesis"},{"key":"915_CR20","doi-asserted-by":"crossref","unstructured":"Durr FE, Wallace RE & Citarella RV (1983) Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 10 Suppl B:3-11","DOI":"10.1016\/0305-7372(83)90016-6"},{"key":"915_CR21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ctrv.2007.01.007","volume":"33","author":"CM Farquhar","year":"2007","unstructured":"Farquhar CM, Marjoribanks J, Lethaby A et al (2007) High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev 33:325\u2013337","journal-title":"Cancer Treat Rev"},{"key":"915_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","volume":"608","author":"AM Gonzalez-Angulo","year":"2007","unstructured":"Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1\u201322","journal-title":"Adv Exp Med Biol"},{"key":"915_CR23","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.2004.08.067","volume":"22","author":"S Gurubhagavatula","year":"2004","unstructured":"Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594\u20132601","journal-title":"J Clin Oncol"},{"key":"915_CR24","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1158\/1078-0432.CCR-07-0252","volume":"13","author":"A Handra-Luca","year":"2007","unstructured":"Handra-Luca A, Hernandez J, Mountzios G et al (2007) Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13:3855\u20133859","journal-title":"Clin Cancer Res"},{"key":"915_CR25","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1158\/1078-0432.CCR-08-3268","volume":"15","author":"M Herrera","year":"2009","unstructured":"Herrera M, Dominguez G, Garcia JM et al (2009) Differences in repair of DNA cross-links between lymphocytes and epithelial tumor cells from colon cancer patients measured in vitro with the comet assay. Clin Cancer Res 15:5466\u20135472","journal-title":"Clin Cancer Res"},{"key":"915_CR26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/carcin\/23.4.599","volume":"23","author":"SM Hou","year":"2002","unstructured":"Hou SM, Falt S, Angelini S et al (2002) The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 23:599\u2013603","journal-title":"Carcinogenesis"},{"key":"915_CR27","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-05-0024","volume":"11","author":"SQ Hutsell","year":"2005","unstructured":"Hutsell SQ, Sancar A (2005) Nucleotide excision repair, oxidative damage, DNA sequence polymorphisms, and cancer treatment. Clin Cancer Res 11:1355\u20131357","journal-title":"Clin Cancer Res"},{"key":"915_CR28","first-page":"1091","volume":"32","author":"H Kamikozuru","year":"2008","unstructured":"Kamikozuru H, Kuramochi H, Hayashi K et al (2008) ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 32:1091\u20131096","journal-title":"Int J Oncol"},{"key":"915_CR29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2217\/14622416.7.6.843","volume":"7","author":"V Le Morvan","year":"2006","unstructured":"Le Morvan V, Bellott R, Moisan F et al (2006) Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-a-vis the NCI-60 panel. Pharmacogenomics 7:843\u2013852","journal-title":"Pharmacogenomics"},{"key":"915_CR30","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2217\/14622416.8.12.1693","volume":"8","author":"V Le Morvan","year":"2007","unstructured":"Le Morvan V, Smith D, Laurand A et al (2007) Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8:1693\u20131703","journal-title":"Pharmacogenomics"},{"key":"915_CR31","doi-asserted-by":"crossref","unstructured":"Lee HW, Han JH, Kim JH et al. (2007) Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer","DOI":"10.1016\/j.lungcan.2007.07.023"},{"key":"915_CR32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1055-9965.EPI-06-1041","volume":"16","author":"J Lin","year":"2007","unstructured":"Lin J, Swan GE, Shields PG et al (2007) Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotype-phenotype correlation. Cancer Epidemiol Biomarkers Prev 16:2065\u20132071","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"915_CR33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/carcin\/21.4.551","volume":"21","author":"RM Lunn","year":"2000","unstructured":"Lunn RM, Helzlsouer KJ, Parshad R et al (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21:551\u2013555","journal-title":"Carcinogenesis"},{"key":"915_CR34","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/carcin\/22.9.1437","volume":"22","author":"G Matullo","year":"2001","unstructured":"Matullo G, Palli D, Peluso M et al (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22:1437\u20131445","journal-title":"Carcinogenesis"},{"key":"915_CR35","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180\u20131184","journal-title":"J Natl Cancer Inst"},{"key":"915_CR36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejca.2006.09.011","volume":"43","author":"CM Nagle","year":"2007","unstructured":"Nagle CM, Chenevix-Trench G, Spurdle AB et al (2007) The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 43:283\u2013290","journal-title":"Eur J Cancer"},{"key":"915_CR37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-004-7751-x","volume":"91","author":"SA Nowell","year":"2005","unstructured":"Nowell SA, Ahn J, Rae JM et al (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249\u2013258","journal-title":"Breast Cancer Res Treat"},{"key":"915_CR38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/JTO.0b013e318031cd89","volume":"2","author":"WJ Petty","year":"2007","unstructured":"Petty WJ, Knight SN, Mosley L et al (2007) A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer. J Thorac Oncol 2:197\u2013202","journal-title":"J Thorac Oncol"},{"key":"915_CR39","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2006.05.8768","volume":"24","author":"M Quintela-Fandino","year":"2006","unstructured":"Quintela-Fandino M, Hitt R, Medina PP et al (2006) DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24:4333\u20134339","journal-title":"J Clin Oncol"},{"key":"915_CR40","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-05-1083","volume":"11","author":"E Reed","year":"2005","unstructured":"Reed E (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11:6100\u20136102","journal-title":"Clin Cancer Res"},{"key":"915_CR41","first-page":"90","volume":"22","author":"E Reed","year":"1995","unstructured":"Reed E, Kohn EC, Sarosy G et al (1995) Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 22:90\u201396","journal-title":"Semin Oncol"},{"key":"915_CR42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1667\/RR3400","volume":"164","author":"J Rzeszowska-Wolny","year":"2005","unstructured":"Rzeszowska-Wolny J, Polanska J, Pietrowska M et al (2005) Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat Res 164:132\u2013140","journal-title":"Radiat Res"},{"key":"915_CR43","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.biocel.2007.05.006","volume":"39","author":"GR Simon","year":"2007","unstructured":"Simon GR, Ismail-Khan R, Bepler G (2007) Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 39:1318\u20131328","journal-title":"Int J Biochem Cell Biol"},{"key":"915_CR44","first-page":"1354","volume":"61","author":"MR Spitz","year":"2001","unstructured":"Spitz MR, Wu X, Wang Y et al (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354\u20131357","journal-title":"Cancer Res"},{"key":"915_CR45","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1158\/1078-0432.CCR-04-1953","volume":"11","author":"R Suk","year":"2005","unstructured":"Suk R, Gurubhagavatula S, Park S et al (2005) Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 11:1534\u20131538","journal-title":"Clin Cancer Res"},{"key":"915_CR46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/carcin\/bgh064","volume":"25","author":"P Vodicka","year":"2004","unstructured":"Vodicka P, Kumar R, Stetina R et al (2004) Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 25:757\u2013763","journal-title":"Carcinogenesis"},{"key":"915_CR47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307\u2013320","journal-title":"Nat Rev Drug Discov"},{"key":"915_CR48","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/FPC.0b013e3280115e63","volume":"17","author":"KJ Wolfe","year":"2007","unstructured":"Wolfe KJ, Wickliffe JK, Hill CE et al (2007) Single nucleotide polymorphisms of the DNA repair gene XPD\/ERCC2 alter mRNA expression. Pharmacogenet Genomics 17:897\u2013905","journal-title":"Pharmacogenet Genomics"},{"key":"915_CR49","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.2005.03.6640","volume":"24","author":"X Wu","year":"2006","unstructured":"Wu X, Gu J, Wu TT et al (2006) Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24:3789\u20133798","journal-title":"J Clin Oncol"},{"key":"915_CR50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/FPC.0b013e32830efdd4","volume":"18","author":"X Wu","year":"2008","unstructured":"Wu X, Lu C, Ye Y et al (2008) Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 18:955\u2013965","journal-title":"Pharmacogenet Genomics"},{"key":"915_CR51","first-page":"3663","volume":"59","author":"CC Zhang","year":"1999","unstructured":"Zhang CC, Yang JM, Bash-Babula J et al (1999) DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res 59:3663\u20133670","journal-title":"Cancer Res"},{"key":"915_CR52","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/138920209788488544","volume":"10","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Rohde LH, Wu H (2009) Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair. Curr Genomics 10:250\u2013258","journal-title":"Curr Genomics"},{"key":"915_CR53","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1158\/1078-0432.CCR-04-0247","volume":"10","author":"W Zhou","year":"2004","unstructured":"Zhou W, Gurubhagavatula S, Liu G et al (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939\u20134943","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-010-0915-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-010-0915-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-010-0915-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T09:15:52Z","timestamp":1685610952000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-010-0915-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,28]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1007\/s00432-010-0915-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,28]]}}}